Skip to content

US · PFSA · MEDICAL - DEVICES

Profusa, Inc. Common Stock (PFSA) intrinsic value and stock valuation

$0.32as of 2026-11-21 · Mkt cap 4.15M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Profusa, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values PFSA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PFSA’s statements →

Profusa, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Berkeley, CA 94710 profusa.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-35.82M
20212025
Free cash flow
-$-16.26M
20212025
Total equity
-$-26.66M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-13.22M-$-4.5M-$-6.07M-$-11.14M-$-11.69M
Net income-$-35.82M-$-9.23M-$-10.28M-$-20.22M-$-10.31M
EPSd-$-108.55M-$-307.67M-$-79.08M-$-63.19M-$-32.22M
Operating cash flow-$-16.25M-$-2.07M-$-4.4M-$-7.7M-$-10.69M
Capital expenditure-$-10K$0.00-$0.00$0.00$0.00
Free cash flow-$-16.26M-$-2.07M-$-4.4M-$-7.7M-$-10.69M
Total assets$3.77M$3.07M$1.89M$1.03M$11.4M
Total debt$14.8M$48.2M$40.4M$31M$24M
Net debt$13M$48M$40.3M$31M$23.2M
Total equity-$-26.66M-$-119.2M-$-110M-$-99.77M-$-83.66M
Cash and short-term investments$1.78M$190K$140K$80K$860K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$2.8M$1.61M$2.04M$4.2M$7.66M
Selling, general and administrative expenses$24.9M$2.99M$4.08M$5.24M$4.77M
Other expenses-$-14.48M-$-100K-$-40K$1.7M-$-740K
Operating expenses$13.2M$4.5M$6.07M$11.1M$11.7M
Cost and expenses$13.2M$4.5M$6.07M$11.1M$11.7M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$5.09M$4.42M$4.28M$6.27M$4.08M
Depreciation and amortization$0.00$0.00$0.00$720K$1.18M
Ebitda-$-30.73M-$-4.81M-$-6M-$-13.22M-$-5.05M
Operating income-$-13.22M-$-4.5M-$-6.07M-$-11.14M-$-11.69M
Total other income/expenses, net-$-22.6M-$-4.73M-$-4.21M-$-9.08M$1.38M
Income before tax-$-35.82M-$-9.23M-$-10.28M-$-20.22M-$-10.31M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-35.82M-$-9.23M-$-10.28M-$-20.22M-$-10.31M
Weighted average shares outstanding$330K$30K$130K$320K$320K
Weighted average diluted shares outstanding$330K$30K$130K$320K$320K
Balance sheet
20252024202320222021
Cash and short-term investments$1.78M$190K$140K$80K$860K
Net receivables$0.00$0.00$40K$0.00$40K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$3.76M$260K$330K$160K$960K
Property, plant and equipment, net$10K$0.00$0.00$0.00$10.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10K$2.81M$1.56M$870K$10.4M
Total assets$3.77M$3.07M$1.89M$1.03M$11.4M
Accounts payable$7.34M$4.95M$3.99M$3.43M$3.26M
Short-term debt$6.94M$48.2M$40.4M$31M$15.8M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$22.3M$57.1M$46.7M$35.7M$21.6M
Long-term debt$7.88M$0.00$0.00$0.00$8.26M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.18M$65.2M$65.2M$65.2M$73.4M
Capital lease obligations$0.00$0.00$0.00$0.00$7.82M
Total liabilities$30.4M$122.3M$111.9M$100.8M$95M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-160.78M-$-124.96M-$-115.73M-$-105.45M-$-85.23M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-26.66M-$-119.2M-$-110M-$-99.77M-$-83.66M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$14.8M$48.2M$40.4M$31M$24M
Net debt$13M$48M$40.3M$31M$23.2M
Cash flow statement
20252024202320222021
Net income-$-35.82M-$-9.23M-$-10.28M-$-20.22M-$-10.31M
Depreciation and amortization$0.00$0.00$0.00$720K$1.18M
Stock-based compensation$890K$20K$30K$110K$70K
Change in working capital$4.35M$2.41M$1.54M$910K-$-520K
Accounts receivable$0.00$40K-$-40K$40K$370K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$3.56M$650K$530K$710K-$-60K
Net cash provided by operating activities-$-16.25M-$-2.07M-$-4.4M-$-7.7M-$-10.69M
Investments in property, plant and equipment-$-10K$0.00-$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-2.01M$0.00-$0.00$0.00$0.00
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19.8M$2.12M$4.47M$6.92M$8.75M
Net change in cash$1.59M$50K$60K-$-780K-$-1.94M
Cash at end of period$1.78M$190K$140K$80K$860K
Operating cash flow-$-16.25M-$-2.07M-$-4.4M-$-7.7M-$-10.69M
Capital expenditure-$-10K$0.00-$0.00$0.00$0.00
Free cash flow-$-16.26M-$-2.07M-$-4.4M-$-7.7M-$-10.69M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Profusa, Inc. Common Stock

        Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological markers. By leveraging artificial intelligence, Profusa translates this constant stream of data into actionable health insights, primarily to empower individuals and clinicians in the management of persistent health challenges like diabetes and critical limb ischemia.

        CEO
        Ben Chung-Bin Hwang
        Employees
        2
        Beta
        0.44

        Explore

        Frequently asked questions

        What is the intrinsic value of Profusa, Inc. Common Stock (PFSA)?

        InvestorsCraft does not currently publish an intrinsic value for PFSA. How the IC value is calculated.

        Is PFSA undervalued?

        InvestorsCraft does not publish an undervaluation signal for PFSA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.